Immunovant Stock Plunges After Credit Suisse Downgrade Citing Unclear Catalysts

Comments
Loading...
  • Credit Suisse downgraded Immunovant Inc IMVT to Underperform from Neutral and lowered the price target to $7 from $12. 
  • Analyst Tiago Fauth says that the downgrade reflects ongoing clinical and regulatory uncertainties for IMVT-1401 owing to safety concerns, likely extended clinical timelines with no clear value-driving catalysts in the next 12-months.
  • According to the analyst, the $200M equity investment from Roivant Sciences has significantly reduced near-term M&A expectations as well.
  • In March, Roivant revealed in an SEC filing to acquire all the shares in Immunovant.
  • Price Action: IMVT shares are down 23.5% at $8 during the market session on the last check Monday.
IMVT Logo
IMVTImmunovant Inc
$18.810.11%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum13.18
Growth-
Quality-
Value-
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm

Posted In: